Shared on08 Aug 25Fair value Decreased 15%
The decrease in Haemonetics' price target primarily reflects a significant reduction in consensus revenue growth forecasts, partially offset by improved net profit margin expectations, leading to a revised fair value of $85.18. What's in the News Haemonetics Corporation (NYSE:HAE) added to Russell 2000 Dynamic Index Valuation Changes Summary of Valuation Changes for Haemonetics The Consensus Analyst Price Target has fallen from $92.45 to $85.18.
Shared on30 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25Fair value Increased 6.88%
AnalystConsensusTarget has increased revenue growth from 4.4% to 5.1%, increased future PE multiple from 16.9x to 21.9x and increased shares outstanding growth rate from -0.1% to -0.0%.
Shared on09 Apr 25Fair value Decreased 0.10%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 3.61%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 0.41%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on11 Mar 25Fair value Decreased 19%
AnalystConsensusTarget has decreased revenue growth from 7.5% to 5.5% and decreased future PE multiple from 23.0x to 20.4x.